MA52199A - Compositions et procédés de traitement de la dystrophie maculaire - Google Patents

Compositions et procédés de traitement de la dystrophie maculaire

Info

Publication number
MA52199A
MA52199A MA052199A MA52199A MA52199A MA 52199 A MA52199 A MA 52199A MA 052199 A MA052199 A MA 052199A MA 52199 A MA52199 A MA 52199A MA 52199 A MA52199 A MA 52199A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
macular dystrophy
dystrophy
Prior art date
Application number
MA052199A
Other languages
English (en)
French (fr)
Inventor
Robert Maclaren
De La Camara Cristina Martinez-Fernandez
Gregory S Robinson
Original Assignee
Nightstarx Ltd
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nightstarx Ltd, Univ Oxford Innovation Ltd filed Critical Nightstarx Ltd
Publication of MA52199A publication Critical patent/MA52199A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052199A 2018-04-05 2019-04-05 Compositions et procédés de traitement de la dystrophie maculaire MA52199A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
MA52199A true MA52199A (fr) 2021-02-17

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052199A MA52199A (fr) 2018-04-05 2019-04-05 Compositions et procédés de traitement de la dystrophie maculaire

Country Status (21)

Country Link
US (2) US20190307900A1 (https=)
EP (1) EP3775233A1 (https=)
JP (1) JP2021520232A (https=)
KR (1) KR20210005040A (https=)
CN (1) CN113056561A (https=)
AU (1) AU2019247864A1 (https=)
BR (1) BR112020020204A2 (https=)
CA (1) CA3096088A1 (https=)
CL (1) CL2020002561A1 (https=)
CO (1) CO2020013690A2 (https=)
EA (1) EA202092069A1 (https=)
IL (1) IL277779A (https=)
JO (1) JOP20200253A1 (https=)
MA (1) MA52199A (https=)
MX (1) MX2020010477A (https=)
PE (1) PE20210918A1 (https=)
PH (1) PH12020551641A1 (https=)
RU (1) RU2020132890A (https=)
SG (1) SG11202009759SA (https=)
TW (1) TW202003052A (https=)
WO (1) WO2019195727A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870148A4 (en) * 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
US20220089670A1 (en) * 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
US20230112568A1 (en) * 2020-02-28 2023-04-13 The Trustees Of The University Of Pennsylvania Treating autosomal recessive bestrophinopathies and methods for evaluating same
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
EP4590841A2 (en) * 2022-09-20 2025-07-30 Aldevron, LLC Best1 vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2307551T3 (pl) * 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Oczyszczanie wektorów retrowirusowych
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
EP3071592B1 (en) * 2013-11-20 2021-01-06 Fondazione Telethon Artificial dna-binding proteins and uses thereof
AU2014359136B2 (en) * 2013-12-06 2020-06-25 Centre Hospitalier Universitaire De Montpellier Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
RS63416B1 (sr) * 2015-03-03 2022-08-31 Fond Telethon Sistem višestrukih vektora i njegove primene
WO2017083722A1 (en) * 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy

Also Published As

Publication number Publication date
KR20210005040A (ko) 2021-01-13
PE20210918A1 (es) 2021-05-19
EA202092069A1 (ru) 2021-03-12
MX2020010477A (es) 2021-03-02
US20230149566A1 (en) 2023-05-18
JP2021520232A (ja) 2021-08-19
CN113056561A (zh) 2021-06-29
JOP20200253A1 (ar) 2020-10-04
CA3096088A1 (en) 2019-10-10
IL277779A (en) 2020-11-30
PH12020551641A1 (en) 2021-07-26
RU2020132890A (ru) 2022-05-06
CO2020013690A2 (es) 2021-04-19
BR112020020204A2 (pt) 2021-01-19
CL2020002561A1 (es) 2021-04-23
AU2019247864A1 (en) 2020-10-22
US20190307900A1 (en) 2019-10-10
EP3775233A1 (en) 2021-02-17
SG11202009759SA (en) 2020-10-29
WO2019195727A1 (en) 2019-10-10
TW202003052A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
EP3720448A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
EP3947715A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3894392A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP3555077A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP3833340A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA
EP3496739A4 (en) COMPOSITIONS AND METHODS FOR TREATING PULMONAL HYPERTENSION
EP3645739A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA
EP3377516A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA47613A (fr) Compositions et procédés de traitement du cancer
EP3612215A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
EP3474879A4 (en) COMPOSITIONS AND METHODS FOR TREATING MELANOMAS
EP3735325A4 (en) SURFACE TREATMENT COMPOSITIONS AND PROCEDURES
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
EP3389672A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF LIVER DISEASES
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
EP3908601A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3448421A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING SURGICAL ADHESIVES
MA55087A (fr) Compositions et procédés de traitement de laminopathies
EP3830196A4 (en) SURFACE TREATMENT COMPOSITIONS AND PROCEDURES
EP4017924A4 (en) SURFACE TREATMENT COMPOSITIONS AND METHODS
EP3405172A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF AGED SKIN